Skip to main content
. 2022 May 12;59(7):4368–4383. doi: 10.1007/s12035-022-02856-w

Fig. 1.

Fig. 1

Schedule of the experimental study. (PIO: pioglitazone; TEL: telmisartan; 3-NP: 3-nitropropionic acid; IHC: immunohistochemistry; WB: Western blot; BW: body weight; OFT: open field test; NOR: novel object recognition test)